Publications

Rendeiro AF, Ravichandran H, Bram Y, Chandar V, Kim J, Meydan C, Park J, Foox J, Hether T, Warren S et al..  2021.  The spatial landscape of lung pathology during COVID-19 progression.. Nature. 593(7860):564-569.

Park J, Foox J, Hether T, Danko D, Warren S, Kim Y, Reeves J, Butler DJ, Mozsary C, Rosiene J et al..  2021.  Systemic Tissue and Cellular Disruption from SARS-CoV-2 Infection revealed in COVID-19 Autopsies and Spatial Omics Tissue Maps.. bioRxiv.

Park J, Foox J, Hether T, Danko D, Warren S, Kim Y, Reeves J, Butler DJ, Mozsary C, Rosiene J et al..  2021.  Systemic Tissue and Cellular Disruption from SARS-CoV-2 Infection revealed in COVID-19 Autopsies and Spatial Omics Tissue Maps.. bioRxiv.

Park J, Foox J, Hether T, Danko D, Warren S, Kim Y, Reeves J, Butler DJ, Mozsary C, Rosiene J et al..  2021.  Systemic Tissue and Cellular Disruption from SARS-CoV-2 Infection revealed in COVID-19 Autopsies and Spatial Omics Tissue Maps.. bioRxiv.

Sugita M, Wilkes DC, Bareja R, Eng KW, Nataraj S, Jimenez-Flores RA, Yan LB, De Leon JPauline, Croyle JA, Kaner J et al..  2021.  Targeting the epichaperome as an effective precision medicine approach in a novel PML-SYK fusion acute myeloid leukemia.. NPJ Precis Oncol. 5(1):44.

Sugita M, Wilkes DC, Bareja R, Eng KW, Nataraj S, Jimenez-Flores RA, Yan LB, De Leon JPauline, Croyle JA, Kaner J et al..  2021.  Targeting the epichaperome as an effective precision medicine approach in a novel PML-SYK fusion acute myeloid leukemia.. NPJ Precis Oncol. 5(1):44.

Sugita M, Wilkes DC, Bareja R, Eng KW, Nataraj S, Jimenez-Flores RA, Yan LB, De Leon JPauline, Croyle JA, Kaner J et al..  2021.  Targeting the epichaperome as an effective precision medicine approach in a novel PML-SYK fusion acute myeloid leukemia.. NPJ Precis Oncol. 5(1):44.

Brady NJ, Bagadion AM, Singh R, Conteduca V, Van Emmenis L, Arceci E, Pakula H, Carelli R, Khani F, Bakht M et al..  2021.  Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer.. Nat Commun. 12(1):3372.

Brady NJ, Bagadion AM, Singh R, Conteduca V, Van Emmenis L, Arceci E, Pakula H, Carelli R, Khani F, Bakht M et al..  2021.  Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer.. Nat Commun. 12(1):3372.

Carrot-Zhang J, Yao X, Devarakonda S, Deshpande A, Damrauer JS, Silva TChedraoui, Wong CK, Choi HYoung, Felau I, A Robertson G et al..  2021.  Whole-genome characterization of lung adenocarcinomas lacking alterations in the RTK/RAS/RAF pathway.. Cell Rep. 34(8):108784.

Carrot-Zhang J, Yao X, Devarakonda S, Deshpande A, Damrauer JS, Silva TChedraoui, Wong CK, Choi HYoung, Felau I, A Robertson G et al..  2021.  Whole-genome characterization of lung adenocarcinomas lacking alterations in the RTK/RAS/RAF pathway.. Cell Rep. 34(8):108784.

Carrot-Zhang J, Yao X, Devarakonda S, Deshpande A, Damrauer JS, Silva TChedraoui, Wong CK, Choi HYoung, Felau I, A Robertson G et al..  2021.  Whole-genome characterization of lung adenocarcinomas lacking alterations in the RTK/RAS/RAF pathway.. Cell Rep. 34(8):108784.

Carrot-Zhang J, Yao X, Devarakonda S, Deshpande A, Damrauer JS, Silva TChedraoui, Wong CK, Choi HYoung, Felau I, A Robertson G et al..  2021.  Whole-genome characterization of lung adenocarcinomas lacking the RTK/RAS/RAF pathway.. Cell Rep. 34(5):108707.

Carrot-Zhang J, Yao X, Devarakonda S, Deshpande A, Damrauer JS, Silva TChedraoui, Wong CK, Choi HYoung, Felau I, A Robertson G et al..  2021.  Whole-genome characterization of lung adenocarcinomas lacking the RTK/RAS/RAF pathway.. Cell Rep. 34(5):108707.

Carrot-Zhang J, Yao X, Devarakonda S, Deshpande A, Damrauer JS, Silva TChedraoui, Wong CK, Choi HYoung, Felau I, A Robertson G et al..  2021.  Whole-genome characterization of lung adenocarcinomas lacking the RTK/RAS/RAF pathway.. Cell Rep. 34(5):108707.

Casiraghi N, Orlando F, Ciani Y, Xiang J, Sboner A, Elemento O, Attard G, Beltran H, Demichelis F, Romanel A.  2020.  ABEMUS: platform-specific and data-informed detection of somatic SNVs in cfDNA.. Bioinformatics. 36(9):2665-2674.

Segal E, Zhang F, Lin X, King G, Shalem O, Shilo S, Allen WE, Alquaddoomi F, Altae-Tran H, Anders S et al..  2020.  Building an international consortium for tracking coronavirus health status.. Nat Med. 26(8):1161-1165.

Segal E, Zhang F, Lin X, King G, Shalem O, Shilo S, Allen WE, Alquaddoomi F, Altae-Tran H, Anders S et al..  2020.  Building an international consortium for tracking coronavirus health status.. Nat Med. 26(8):1161-1165.

Segal E, Zhang F, Lin X, King G, Shalem O, Shilo S, Allen WE, Alquaddoomi F, Altae-Tran H, Anders S et al..  2020.  Building an international consortium for tracking coronavirus health status.. Nat Med. 26(8):1161-1165.

Segal E, Zhang F, Lin X, King G, Shalem O, Shilo S, Allen WE, Alquaddoomi F, Altae-Tran H, Anders S et al..  2020.  Building an international consortium for tracking coronavirus health status.. Nat Med. 26(8):1161-1165.

Beltran H, Romanel A, Conteduca V, Casiraghi N, Sigouros M, Franceschini GMarco, Orlando F, Fedrizzi T, Ku S-Y, Dann E et al..  2020.  Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer.. J Clin Invest. 130(4):1653-1668.

Vosoughi A, Zhang T, Shohdy KS, Vlachostergios PJ, Wilkes DC, Bhinder B, Tagawa ST, Nanus DM, Molina AM, Beltran H et al..  2020.  Common germline-somatic variant interactions in advanced urothelial cancer.. Nat Commun. 11(1):6195.

Vosoughi A, Zhang T, Shohdy KS, Vlachostergios PJ, Wilkes DC, Bhinder B, Tagawa ST, Nanus DM, Molina AM, Beltran H et al..  2020.  Common germline-somatic variant interactions in advanced urothelial cancer.. Nat Commun. 11(1):6195.

Lourenco ARita, Ban Y, Crowley MJ, Lee SB, Ramchandani D, Du W, Elemento O, George JT, Jolly MKumar, Levine H et al..  2020.  Differential Contributions of Pre- and Post-EMT Tumor Cells in Breast Cancer Metastasis.. Cancer Res. 80(2):163-169.

Dalton T, Doubrovina E, Pankov D, Reynolds R, Scholze H, Selvakumar A, Vizconde T, Savalia B, Dyomin V, Weigel C et al..  2020.  Epigenetic reprogramming sensitizes immunologically silent EBV+ lymphomas to virus-directed immunotherapy.. Blood. 135(21):1870-1881.